Mohammad Karim Haidar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammad Karim Haidar has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Emirhan Nemutlu
Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey
3 shared publications- Hakan Eroglu
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
3 shared publications Kezban Ulubayram
Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Hacettepe University 06100, Ankara, Turkey
3 shared publicationsLevent Öner
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey
3 shared publicationsMitsuru Hashida
Kyoto University Graduate School of Pharmaceutical Science, Department of Drug Delivery Research, Kyoto, Japan
2 shared publicationsSelin Seda Timur
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey
2 shared publications
Latest Publications
- 30 December 2021
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 18 (6) , 752-760
Minocycline Hydrochloride Controlled-release Microsphere Preparation Process Optimization Based on the Robust Design Method
The objective of the present study is to establish a robust preparation method that could steadily produce minocycline hydrochloride (MCH) microspheres regardless of used polymer types. Taguchi’s Robust Experimental Design methodology was employed to optimize the process parameters for MCH-loaded poly(D,L-lactide-co-glycolide) (PLGA) microspheres. In the experimental design, seven controllable factors, i.e., preparation method, pH of the aqueous phase, volume of the aqueous phase, volume of dichloromethane, rotation speed, temperature, and amount of polyvinyl alcohol, were considered for the optimization of process parameters. PLGA types with different lactide/glycolide ratios were considered the uncontrollable (noise) factor. Based on the L18 orthogonal array, 18 experimental runs were conducted for each type of PLGA. The encapsulation efficiency (EE) and in vitro release rate were evaluated for all the prepared formulations. Regardless of the PLGA type with different lactic/glycolic acid ratios, microspheres prepared via the solid-in-oil-in-water (S/O/W) method, showed a much higher EE and faster drug release than the microspheres prepared via the co-solvent method. Preparation methods, pH of the aqueous phase, and volume of the aqueous phase were the most influencing parameters on the EE. The confirmation experiment results indicated that the signal-to-noise ratio increased by 5.76 db from that of an initial condition. The release of minocycline was fastest with the PLGA (50:50) microspheres, followed by PLGA (75:25) and PLGA (85:15). Although the interaction between the selected factors in the evaluation was ignored, the orthogonal array design of the experiment based on Taguchi’s robust experimental design methodology was sufficient to optimize the process parameters for the PLGA microspheres of MCH. The S/O/W was the main factor affecting the EE. Microspheres prepared via the S/O/W method exhibited a higher EE and faster drug release than the microspheres prepared via co-solvent method. The pH and volume of the aqueous phase were also effective parameters on the EE. A robust experimental design has been successfully applied to the optimization of the process parameters for microsphere preparation.
- 30 December 2021
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 18 (6) , 752-760
Minocycline Hydrochloride Controlled-release Microsphere Preparation Process Optimization Based on the Robust Design Method
The objective of the present study is to establish a robust preparation method that could steadily produce minocycline hydrochloride (MCH) microspheres regardless of used polymer types. Taguchi’s Robust Experimental Design methodology was employed to optimize the process parameters for MCH-loaded poly(D,L-lactide-co-glycolide) (PLGA) microspheres. In the experimental design, seven controllable factors, i.e., preparation method, pH of the aqueous phase, volume of the aqueous phase, volume of dichloromethane, rotation speed, temperature, and amount of polyvinyl alcohol, were considered for the optimization of process parameters. PLGA types with different lactide/glycolide ratios were considered the uncontrollable (noise) factor. Based on the L18 orthogonal array, 18 experimental runs were conducted for each type of PLGA. The encapsulation efficiency (EE) and in vitro release rate were evaluated for all the prepared formulations. Regardless of the PLGA type with different lactic/glycolic acid ratios, microspheres prepared via the solid-in-oil-in-water (S/O/W) method, showed a much higher EE and faster drug release than the microspheres prepared via the co-solvent method. Preparation methods, pH of the aqueous phase, and volume of the aqueous phase were the most influencing parameters on the EE. The confirmation experiment results indicated that the signal-to-noise ratio increased by 5.76 db from that of an initial condition. The release of minocycline was fastest with the PLGA (50:50) microspheres, followed by PLGA (75:25) and PLGA (85:15). Although the interaction between the selected factors in the evaluation was ignored, the orthogonal array design of the experiment based on Taguchi’s robust experimental design methodology was sufficient to optimize the process parameters for the PLGA microspheres of MCH. The S/O/W was the main factor affecting the EE. Microspheres prepared via the S/O/W method exhibited a higher EE and faster drug release than the microspheres prepared via co-solvent method. The pH and volume of the aqueous phase were also effective parameters on the EE. A robust experimental design has been successfully applied to the optimization of the process parameters for microsphere preparation.
- 1 June 2020
- Published by Emerald Publishing in Bioinspired, Biomimetic and Nanobiomaterials
- Vol. 9 (2) , 74-84
Atorvastatin-loaded nanosprayed chitosan nanoparticles for peripheral nerve injury
In this study, chitosan nanoparticles containing atorvastatin calcium were prepared using the nanospray-drying method to be used in the local treatment of peripheral nerve injuries. The main focus was to investigate the effect of the molecular weight and concentration of the polymer, the concentration of the active pharmaceutical ingredient and the diameter of the spray nozzle (4·0, 5·5 and 7·0 μm) on the final properties of nanoparticles. Atorvastatin nanoparticles were characterized in terms of morphology, particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency and in vitro release. In all formulations, the nanoparticles were found to be in the submicrometer range (510·5 ± 22·3–820·0 ± 98·7 nm) with a positive surface charge (11·1–26·6 mV) and a narrow particle size distribution (PDI = 0·10–0·58). Further evaluation of the synthesized nanoparticles revealed high encapsulation efficiency (23·37–53·61%) and production yield (58·30–74·10%). Critical examination of the morphology of nanoparticles in all formulations indicated that the nanoparticles were almost spherical in shape and had a wrinkled surface. The in vitro release test revealed that the nanoparticles were capable of maintaining a sustained release of atorvastatin for about 200 h. The cytotoxicity of chitosan nanoparticles was evaluated using L-929 and B35 cells, and the nanoparticles were found to show no toxic effect.
- 1 June 2020
- Published by Emerald Publishing in Bioinspired, Biomimetic and Nanobiomaterials
- Vol. 9 (2) , 74-84
Atorvastatin-loaded nanosprayed chitosan nanoparticles for peripheral nerve injury
In this study, chitosan nanoparticles containing atorvastatin calcium were prepared using the nanospray-drying method to be used in the local treatment of peripheral nerve injuries. The main focus was to investigate the effect of the molecular weight and concentration of the polymer, the concentration of the active pharmaceutical ingredient and the diameter of the spray nozzle (4·0, 5·5 and 7·0 μm) on the final properties of nanoparticles. Atorvastatin nanoparticles were characterized in terms of morphology, particle size, polydispersity index (PDI), zeta potential, encapsulation efficiency and in vitro release. In all formulations, the nanoparticles were found to be in the submicrometer range (510·5 ± 22·3–820·0 ± 98·7 nm) with a positive surface charge (11·1–26·6 mV) and a narrow particle size distribution (PDI = 0·10–0·58). Further evaluation of the synthesized nanoparticles revealed high encapsulation efficiency (23·37–53·61%) and production yield (58·30–74·10%). Critical examination of the morphology of nanoparticles in all formulations indicated that the nanoparticles were almost spherical in shape and had a wrinkled surface. The in vitro release test revealed that the nanoparticles were capable of maintaining a sustained release of atorvastatin for about 200 h. The cytotoxicity of chitosan nanoparticles was evaluated using L-929 and B35 cells, and the nanoparticles were found to show no toxic effect.
- 4 April 2017
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 17 (13) , 1564-1579
Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Nanofibers became one of the major research areas for drug delivery and tissue engineering applications in the last decade. Depending on the simplicity of the preparation method and high drug loading capacity, nanofibers provide many advantages for therapeutic perspectives. In addition, combined systems such as embedding nanoparticles into the nanofiber structures provide a second option for delivery of dual active ingredients in the same formulation. The release rate of the active ingredients can also be modified easily by the formulation parameters depending on the desired release time for treatment. Nanofibers systems are used for the delivery of antibiotics, anticancer drugs, analgesics, hemostatic agents and various proteins for tissue engineering purposes. In addition, various applications such as medical device coating also provide new insights for the clinical use of nanofibers. The most commonly used technique for preparation of nanofibers is the electrospinning, which provides feasibility background for scale up process from laboratory to the industrial applications. The main boundary for nanofibers is the limitations for systemic route. Nanofibers are mainly designed for the delivery of active ingredients for local purposes. Regardless of the therapeutic aim, nanofibers are also perfect 3 dimensional structures that are suitable for tissue regeneration. They provide matrix structure for cell regeneration especially in applications for wound healing. This review is mainly focused on the recent advances on the preparation of nanofibers, applications for drug delivery, tissue engineering and wound healing purposes.
- 4 April 2017
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 17 (13) , 1564-1579
Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Nanofibers became one of the major research areas for drug delivery and tissue engineering applications in the last decade. Depending on the simplicity of the preparation method and high drug loading capacity, nanofibers provide many advantages for therapeutic perspectives. In addition, combined systems such as embedding nanoparticles into the nanofiber structures provide a second option for delivery of dual active ingredients in the same formulation. The release rate of the active ingredients can also be modified easily by the formulation parameters depending on the desired release time for treatment. Nanofibers systems are used for the delivery of antibiotics, anticancer drugs, analgesics, hemostatic agents and various proteins for tissue engineering purposes. In addition, various applications such as medical device coating also provide new insights for the clinical use of nanofibers. The most commonly used technique for preparation of nanofibers is the electrospinning, which provides feasibility background for scale up process from laboratory to the industrial applications. The main boundary for nanofibers is the limitations for systemic route. Nanofibers are mainly designed for the delivery of active ingredients for local purposes. Regardless of the therapeutic aim, nanofibers are also perfect 3 dimensional structures that are suitable for tissue regeneration. They provide matrix structure for cell regeneration especially in applications for wound healing. This review is mainly focused on the recent advances on the preparation of nanofibers, applications for drug delivery, tissue engineering and wound healing purposes.
- 1 August 2010
- Published by Elsevier in Computers & Chemical Engineering
- Vol. 34 (8) , 1306-1311
A novel multi-dimensional visualization technique for understanding the design parameters of drug formulations
- 1 August 2010
- Published by Elsevier in Computers & Chemical Engineering
- Vol. 34 (8) , 1306-1311
A novel multi-dimensional visualization technique for understanding the design parameters of drug formulations